Problem Solving in Cancer Immunotherapy
Description
A broad and experienced team, including medical oncologists and life scientists, have collaborated to produce this practical guide to cancer immunotherapy. It provides a compendium of best practice, including 23 case studies to act as models for professionals to make decisions, either for individual patients or as the basis for using immunotherapy across an organisation, planning area, region or country. As well as introducing all key concepts, expert practitioners provide a guide to future treatments using novel technologies, discuss key problems and suggest solutions, and consider the costs of immunotherapy treatments.This guide also makes an excellent training tool, which will help new teams and clinical staff to develop procedures, and adopt best practice. This resource is produced in partnership with the Association of Cancer Physicians (ACP).
All prices
More details
Other editions
Additional editions
Content
- Front Cover
- Half Title
- Title page
- Copyright page
- Contents
- Contributors
- Preface
- Acknowledgements
- Abbreviations
- SECTION ONE
- 01 Immunotherapy: Past, Present and Future
- 02 Beyond Exhausted: Tumour Immune Checkpoints and Their Therapeutic Targets
- 03 Immune Checkpoint Inhibitors: Successes and Challenges
- 04 Immune-Related Toxicity of Checkpoint Inhibitors
- 05 Predicting Response to Immunotherapy
- 06 Difficulties in Assessment of PD-L1 Expression
- 07 Radiological Assessment of Immunotherapy
- 08 Combination Immunotherapies: Multimodality Treatment
- 09 Future Vaccine Strategies in Cancer Immunotherapy
- 10 Genetically-Modified Cell Therapy for Solid Tumours
- 11 Adoptive T Cell Therapy for Haematological Malignancies
- 12 Tumour-Infiltrating Lymphocytes
- SECTON TWO
- 01 Cytokine Release Syndrome
- 02 High-Dose Interleukin-2-Induced Myocarditis
- 03 Multiorgan Toxicity after Combination Immunotherapy in Melanoma
- 04 Immune-Related Endocrine Toxicity after Immune Checkpoint Inhibitor Therapy
- 05 Immune Checkpoint Inhibitors in Patients with Autoimmune Disease
- 06 A Patient with Lung Cancer Who Received an Immune Checkpoint Inhibitor in the First Line Setting
- 07 Sinonasal Mucosal Malignant Melanoma
- 08 Adjuvant Immunotherapy in Metastatic Melanoma
- 09 Ongoing Response after Stopping Immunotherapy
- 10 Pneumonitis after Treatment with an Anti-PD-1 Antibody in a Patient with Non-Small-Cell Lung Carcinoma
- 11 Colitis after Combination Immunotherapy in a Clinical Study of Small-Cell Lung Cancer
- 12 Jaundice after Pembrolizumab in a Patient with Melanoma and Brain Metastases
- 13 Localized Scleroderma in a Patientwith Metastatic Melanoma Treated with Pembrolizumab
- 14 Intracranial Melanoma Response to Combination Ipilimumab and Nivolumab
- 15 Delayed Response to Immunotherapy in a Patient with Acral Melanoma
- 16 Facial Nerve Palsy in a Patient with Renal Cell Carcinoma Treated with Nivolumab
- 17 Acute Kidney Injury in a Patient on Combination Immunotherapy for Metastatic Melanoma
- 18 Immune Pneumonitis after Immunotherapy for Metastatic Melanoma
- 19 A Patient with Ureteric Transitional Cell Carcinoma on Anti-PD-1 Antibody Complicated by Sarcoidosis
- 20 Renal Cell Carcinoma Treated with Ipilimumab and Nivolumab
- 21 Ocular Toxicity from Nivolumab
- 22 Multiple Immune-Related Toxicitiesin a Patient with Breast Cancer on Immune Checkpoint Inhibition and Chemotherapy
- 23 Oncolytic Viral Therapy: Talimogene Laherparepvec
- Index
- Back Cover
